TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02917434

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Energy Diet (VLED)
Description: Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Very Low Energy Diet (VLED)
Description: Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.
Study: NCT02201992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study: NCT00002816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study: NCT01907464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: para clinical parameters description
Description: description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: para clinical parameters description
Description: description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hormonal parameters dosing
Description: dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hormonal parameters dosing
Description: dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
Study: NCT00002816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study: NCT02201992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01907464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone modeling markers dosing
Description: dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bone modeling markers dosing
Description: dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
Study: NCT01128426

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT03604029

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Near Infrared Spectroscopy (NIRS) sensors are applied to injured leg compartments and a control compartment to continuously measure tissue oxygenation.

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Near Infrared Spectroscopy (NIRS) sensors are applied to injured leg compartments and a control compartment to continuously measure tissue oxygenation.
Study: NCT01922271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18 μg once daily delivered via HandiHaler® device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to NVA237
Description: Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium once daily delivered via HandiHaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Used as resuce medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Used as resuce medication
Study: NCT02442024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Diet
Description: Two months of a diet in which the ingestion of protein and lipid precedes that of carbohydrates.
Study: NCT03333564

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention was given
Study: NCT02442024

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diet
Description: Two months of a diet in which the ingestion of protein and lipid follows that of carbohydrates.
Study: NCT01094535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic Human Secretin
Description: S-MRCP has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in the pancreatic ducts, as well as functional secretory capacity of the gland. Twelve patients will each undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations, at a dose of 0.2 ucg/kg per exam, each S-MRCP will require 16-32 ucg of secretin (12 vials). Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
Study: NCT00002816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study: NCT00379639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 7, 10 or 12 mg/m\^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 800 or 1000 mg/m\^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
Study: NCT02201992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00087516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin (MK0431)
Description: Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
Study: NCT02724189

Intervention type: DEVICE
Intervention: MyPreOp assessment
Description: MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.

Intervention type: OTHER
Intervention: Nurse led assessment
Description: Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
Study: NCT04483726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive distal pancreatectomy
Description: Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: open distal pancreatectomy
Description: open distal pancreatectomy
Study: NCT02330055

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forty-five degrees elevated upper body position

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non-elevated upper body position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive wrist pulse oximeter (WristOx Model 3150)
Description: The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Noninvasive wrist pulse oximeter (WristOx Model 3150)
Description: The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stop-Bang questionnaire
Description: The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.~The investigators will ask the patient to answer the questionnaire and measure the neck circumference.
Study: NCT03831711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI
Study: NCT02330055

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stop-Bang questionnaire
Description: The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.~The investigators will ask the patient to answer the questionnaire and measure the neck circumference.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epworth Sleepiness Scale
Description: The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.~The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Epworth Sleepiness Scale
Description: The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.~The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P-SAP Score
Description: The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.~The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: P-SAP Score
Description: The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.~The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-reported pain
Description: A verbal numerical rating scale is used to asses the pain during the study-night.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: self-reported pain
Description: A verbal numerical rating scale is used to asses the pain during the study-night.
Study: NCT00002816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study: NCT02611492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: 400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aracytine (Ara C)
Description: Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF)
Description: 5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF)
Description: 5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depomedrol
Description: 40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depomedrol
Description: 40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: 300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 Mercaptopurine (6MP)
Description: 60 mg/m2 per os, D1 to D14, interphase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 Mercaptopurine (6MP)
Description: 60 mg/m2 per os, D1 to D14, interphase
Study: NCT02852265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel contraceptive implant
Description: Place nexplanon
Study: NCT03469921

Intervention type: DRUG
Intervention: administered therapeutic regimens
Description: administered therapeutic regimens

Intervention type: DRUG
Intervention: administered therapeutic regimens
Description: administered therapeutic regimens

Intervention type: DRUG
Intervention: administered therapeutic regimens
Description: administered therapeutic regimens
Study: NCT00087516

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
Study: NCT02727374

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy intervention
Description: Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Description: Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural Intervention
Description: Psychological treatment consists of group talks to treat the fear to fall
Study: NCT02892916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A bolus of an intravenous normal saline solution following induction of anaesthesia.
Study: NCT03991520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe
Description: The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
Study: NCT03542864

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nasogastroduodenal Protocol
Description: Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Progress registration of body composition values

Intervention type: OTHER
Group type: OTHER
Intervention: Data analysis
Description: Statistical analysis of all data
Study: NCT03107065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermi Radiofrequency
Description: Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
Study: NCT04535518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: IVIG at a single dose of 2 g/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: IVIG at a single dose of 2 g/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
Study: NCT03843866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4-0 Monocryl
Description: sutures and steri-strips

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive Glue
Description: Adhesive Glue
Study: NCT01920269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-urethral resection
Description: Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.
Study: NCT03469921

Intervention type: DRUG
Intervention: administered therapeutic regimens
Description: administered therapeutic regimens

Intervention type: DRUG
Intervention: administered therapeutic regimens
Description: administered therapeutic regimens
Study: NCT02472574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YL-1 type of intracranial hematoma puncture needle
Description: YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.
Study: NCT03469921

Intervention type: DRUG
Intervention: administered therapeutic regimens
Description: administered therapeutic regimens

Intervention type: DRUG
Intervention: administered therapeutic regimens
Description: administered therapeutic regimens

Intervention type: DRUG
Intervention: administered therapeutic regimens
Description: administered therapeutic regimens

Intervention type: DRUG
Intervention: administered therapeutic regimens
Description: administered therapeutic regimens

Intervention type: DRUG
Intervention: administered therapeutic regimens
Description: administered therapeutic regimens